SAN PEDRO, Calif.--(BUSINESS WIRE)--Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have successfully isolated and propagated Human Triple Negative Breast cancer stem cells. Breast Cancer is most common malignancy among women in developed countries, affecting more than a million women per year worldwide. Of these, Triple Negative Breast Carcinoma represents 10-17%.
